
McKesson Corporation (MCK)
$
811.34
-14.19 (-1.75%)
Key metrics
Financial statements
Free cash flow per share
45.9888
Market cap
100.1 Billion
Price to sales ratio
0.2650
Debt to equity
-5.0498
Current ratio
0.8829
Income quality
1.9809
Average inventory
24 Billion
ROE
-1.2479
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides a wide range of healthcare services both in the United States and internationally. The company operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment is involved in the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, along with other healthcare-related products. Additionally, this segment offers practice management, technology, clinical support, and business solutions tailored for community-based oncology and other specialty practices. It also provides consulting, outsourcing, technological, and various services while selling financial, operational, and clinical solutions to pharmacies. The International segment serves wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on distributing medical-surgical supplies, logistics, and other essential services to healthcare providers. Meanwhile, the RxTS segment caters to biopharma and life sciences partners, addressing medication challenges throughout patient journeys; it connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions while also providing third-party logistics and wholesale distribution support solutions. The company reported depreciation and amortization expenses of $636,000,000.00 reflecting the wear and tear of its assets. Its selling, general, and administrative expenses total $8,022,000,000.00 indicating operational overhead costs. The interest income earned amounting to $173,000,000.00 showcases its financial investments. Overall, the total costs and expenses for the company are $354,679,000,000.00 reflecting comprehensive spending, while the EBITDA stands at $5,251,000,000.00 a key indicator of the company's operational profitability. In the financial marketplace, the stock is priced at $698.31 positioning it in the higher-end market. It has an average trading volume of 772,848.00 indicating moderate liquidity in its trading activities. With a significant market capitalization of $100,918,033,417.00 McKesson Corporation establishes itself as a dominant player in the healthcare industry. The company is an essential participant in the Medical - Distribution industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its domain.
Investing in McKesson Corporation (MCK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict McKesson Corporation stock to fluctuate between $520.20 (low) and $846.32 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-10-31, McKesson Corporation's market cap is $100,918,033,417, based on 124,384,393 outstanding shares.
Compared to Eli Lilly & Co., McKesson Corporation has a Lower Market-Cap, indicating a difference in performance.
McKesson Corporation pays dividends. The current dividend yield is 0.38%, with a payout of $0.82 per share.
To buy McKesson Corporation (MCK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MCK. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
McKesson Corporation's last stock split was 2:1 on 1998-01-05.
Revenue: $359,051,000,000 | EPS: $25.86 | Growth: 14.73%.
Visit https://www.mckesson.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $846.32 (2025-10-30) | All-time low: $192.38 (2021-08-10).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

zacks.com
Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
zacks.com
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com
McKesson (MCK) reached $801.67 at the closing of the latest trading day, reflecting a +1.1% change compared to its last close.

zacks.com
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.

zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.

zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

seekingalpha.com
McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM Vision, Core Ventures) and organizational restructuring position MCK for sustained growth in oncology, multispecialty, and technology-enabled segments. Q1 FY26 results showed strong revenue growth, robust cash flow guidance, and raised long-term EPS targets, reflecting confidence in durable earnings momentum.

seekingalpha.com
McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology Solutions. MCK's upgraded long-term adjusted EPS growth target of 13%-16%, aggressive capital returns, and strategic realignment support a bullish outlook and potential for significant stock price appreciation by FY2030. Key risks include regulatory pressure on U.S. drug pricing, opioid litigation overhangs, execution risks in acquisitions and divestitures, and high customer concentration, which may cause volatility or corrections.

zacks.com
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
See all news